🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)Okay who else cannot stop burping Page 5

Okay who else cannot stop burping

NauseaFreeNow Sat, Mar 28, 2026 at 6:19 AM 32 replies 1,270 viewsPage 5 of 7
AttorneyGrant
Member
567
2,890
Apr 2024
Washington, DC
Apr 7, 2026 at 8:48 PM#21
PharmHunterJen said:
Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then…

Coming at PharmHunterJen’s question from a different direction. The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

Last edited: Apr 7, 2026 at 9:48 PM
24 22Dr.SleepRoch, laura_annarbor, JenMemphis and 21 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Apr 11, 2026 at 9:52 PM#22

Adding the numbers, since they settle part of this. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.

25 23Admin, Dr.Martinez, mike_mod and 22 others
Reply Quote Save Share Report
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Apr 15, 2026 at 10:55 PM#23

A narrower follow-up, since the general answer is now clear:

What the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss?

26 24MeganSA_TX, LarryQC_SD, wanda_boise and 23 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Apr 19, 2026 at 11:55 PM#24
FDA_TrackerJim said:
Say what you would expect to see if you were wrong, before you look.

Careful with the causal language. Two things moving together in a period when five things changed is not a mechanism, and stating it as one makes the thread less useful to somebody reading it later.

Last edited: Apr 20, 2026 at 4:55 AM
27 0SkepticalSean, Dr.CardioMD, EndoResFellow and 24 others
Reply Quote Save Share Report
pete_manc_UK
Senior Member
1,234
5,678
Mar 2024
Manchester, UK
Apr 24, 2026 at 12:53 AM#25
FDA_TrackerJim said:
Say what you would expect to see if you were wrong, before you look.

Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.

I would rather be corrected than agreed with, if it comes to it.

28 1mike.trainer_LA, sarah_nash92, FitDadDave and 25 others
Reply Quote Save Share Report

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register